Literature DB >> 487647

Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.

N Thatcher, R Swindell, D Crowther.   

Abstract

Two groups, each of eight patients, with metastatic melanoma were immunized with either C. parvum or BCG at 3-weekly intervals. The serum IgG, IgA, IgM levels, E-rosettes, EA-rosetts, sIg-bearing cells, 'null cells' and lymphocyte blastogenesis at four PHA concentrations were assayed, before immunization and weekly thereafter for 8 weeks. The pre-immunization E-rosette values were significantly reduced, with a significant increase in 'null cell' values and EA-rosette percentages, when compared with healthy controls. Following C. parvum immunization, significant increases occurred in E-rosette percentages with decreases in EA-rosette and 'null cell' counts. A significant reduction in 'null cell' values also occurred with BCG. Other parameters including PHA blastogenesis did not exhibit statistically significant changes. Different methods of expressing the results (particularly of blastogenesis data) were compared, as were the similarities between the present investigation and a study of the effects of a single immunization. The relationship between the subpopulation changes and lymphocyte cytotoxicity described in an earlier article (Thatcher, Swindell & Crowther, 1979a) is discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 487647      PMCID: PMC1537740     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

Review 1.  Antitumor activity of Corynebacterium parvum.

Authors:  L Milas; M T Scott
Journal:  Adv Cancer Res       Date:  1978       Impact factor: 6.242

2.  Correlation of in vivo and in vitro assays of immunocompetence in cancer patients.

Authors:  S H Golub; T X O'Connell; D L Morton
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

3.  Lymphocyte function related to survival curves in patients with metastatic melanoma treated by chemoimmunotherapy.

Authors:  N Thatcher; M K Palmer; R Swindell; D Crowther
Journal:  Med Pediatr Oncol       Date:  1978

4.  Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.

Authors:  N Thatcher; R Swindell; D Crowther
Journal:  Clin Exp Immunol       Date:  1979-01       Impact factor: 4.330

5.  Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.

Authors:  N Thatcher; R Swindell; D Crowther
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

6.  Immunological monitoring and immunotherapy in carcinoma of the lung.

Authors:  J L Weese; R B Herberman; E Perlin; M Mills; W Heims; J Blom; D Green; J Reid; S Bellinger; I Law; J L McCoy; J H Dean; G B Cannon; J Djeu
Journal:  Int J Cancer       Date:  1976-12-15       Impact factor: 7.396

7.  Sequential examination of lymphocyte proliferative capacity in patients with malignant melanoma receiving BCG immunotherapy.

Authors:  S H Golub; A B Forsythe; D L Morton
Journal:  Int J Cancer       Date:  1977-01       Impact factor: 7.396

8.  Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy.

Authors:  V K Lui; J Karpuchas; P B Dent; P B McCulloch; M A Blajchman
Journal:  Br J Cancer       Date:  1975-09       Impact factor: 7.640

9.  Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.

Authors:  N Thatcher; M K Palmer; N Gasiunas; D Crowther
Journal:  Br J Cancer       Date:  1977-12       Impact factor: 7.640

10.  The effect of Corynebacterium parvum therapy on immunoglobulin class and IgG subclass levels in cancer patients.

Authors:  K James; G J Clunie; M F Woodruff; W H McBride; W H Stimson; R Drew; D Catty
Journal:  Br J Cancer       Date:  1975-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.